Table 1.
Demographic and clinical findings of volunteers received the Oxford-AstraZeneca and Sinopharm vaccines (n = 221).
| Healthy subjects (n = 121) | Patients with SLE (n = 26) | Patients with SSc (n = 15) | Patients with as (n = 21) | Patients with RA (n = 38) | |
|---|---|---|---|---|---|
| Age, years, median (range) | 46.11 ± 12.49 (19-75) | 49.93 ± 9.5 (35–65) | 31.7 ± 6.7 (19–63) | 42.15 ± 12.29 (21–65) | 52.62 ± 11.98 (25–75) |
| Gender, female, n (%) | 63 (52 %) | 24 (96%) | 15 (100%) | 4 (15.3%) | 32 (84.2%) |
| Smoking history | 9 (7.43%) | 2 (8%) | 0 (0.0%) | 4 (15.3%) | 4 (10.52%) |
| Disease duration, years, median (range) | - | 8.07 ± 3.8 (2–18) | 6.5 ± 3.8 (4–14) | 4.9 ± 2.3(3–10) | 8.2 ± 4.16 (3–18) |
| Background diseases | - | Diabetes: 4 | - | ||
| Hypertension:2 | Diabetes: 2 | Diabetes: 3 | |||
| Hyperlipidemia: 2 | Other | Hypertension: 6 | |||
| Anemia: 1 | metabolic disorders: 1 | Hyperlipidemia: 6 | |||
| Other metabolic disorders: 2 | Other metabolic disorders: 1 | ||||
| Myalgia | 20 (16.52%) | 7 (26.9%) | 0 (0.0%) | 3 (14.2%) | 6 (15.7%) |
| Fever | 8 (6.61%) | 2 (7.69%) | 1 (6.6%) | 3 (14.2%) | 2 (5.23%) |
| Headache | 13 (0.0%) | 2 (7.69%) | 0 (0.0%) | 2 (13.3%) | 4 (10.46%) |
| Natural history of COVID-19 | 46 (38.01%) | 17 (65.38%) | 4 (26.6%) | 7 (33.3%) | 21(55.26%) |
| Skin lesions | 1 (0.8%) | 1 (3.84%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Concomitant immunosuppressive medications, n (%) | |||||
| Methotrexate | 0 (0.0%) | 0 (0.0%) | 12 (80%) | 0 (0.0%) | 30 (78.90%) |
| Glucocorticoid | 0 (0.0%) | 26 (100%) | 14 (93.3%) | 0 (0.0%) | 38 (100%) |
| Mycophenolate mofetil | 0 (0.0%) | 23 (88.4%) | 13 (86.6%) | 0 (0.0%) | 0 (0.0%) |
| Hydroxyl chloroquine | 0 (0.0%) | 24 (92.3%) | 0 (0.0%) | 0 (0.0%) | 30 (78.90%) |
| Sulfasalazine | 0 (0.0%) | 4 (15.3%) | 5 (33.3 %) | 18 (85.7%) | 3 (7.8%) |
| Anti-TNF | 0 (0.0%) | 3 (11.5%) | 1 (6.6%) | 20 (95.2%) | 0 (0.0%) |
SLE: systemic lupus erythematosus; SSc: systemic sclerosis; AS: ankylosing spondylitis; RA, rheumatoid arthritis.